at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Company profile
Ticker
ILMN
Exchange
Website
CEO
Francis deSouza
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ILLUMINA INC
SEC CIK
Corporate docs
Subsidiaries
Advanced Liquid Logic Inc. • BlueBee Holding BV • Conexio Genomics Pty Ltd. • Emedgene Technologies Ltd • GRAIL, LLC • IDbyDNA Inc. • Illumina AB • Illumina Australia • Illumina Austria GmbH • Illumina Belgium BV ...
IRS number
330804655
ILMN stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
20 May 24
8-K
Submission of Matters to a Vote of Security Holders
20 May 24
8-K/A
Cost Associated with Exit or Disposal Activities
3 May 24
10-Q
2024 Q1
Quarterly report
3 May 24
8-K
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
2 May 24
8-K
Regulation FD Disclosure
12 Apr 24
8-K
Jakob Wedel Chief Strategy and Corporate Development Officer
9 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
Transcripts
ILMN
Earnings call transcript
2024 Q1
2 May 24
ILMN
Earnings call transcript
2023 Q4
8 Feb 24
ILMN
Earnings call transcript
2023 Q3
9 Nov 23
ILMN
Earnings call transcript
2023 Q2
9 Aug 23
ILMN
Earnings call transcript
2023 Q2
9 Aug 23
ILMN
Earnings call transcript
2023 Q1
25 Apr 23
ILMN
Earnings call transcript
2022 Q4
7 Feb 23
ILMN
Earnings call transcript
2022 Q3
4 Nov 22
ILMN
Earnings call transcript
2022 Q2
11 Aug 22
ILMN
Earnings call transcript
2022 Q1
6 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Oct 23 | Jul 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Jan 23 | Jan 22 | Jan 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.11 bn | 1.11 bn | 1.11 bn | 1.11 bn | 1.11 bn | 1.11 bn |
Cash burn (monthly) | (no burn) | 32.17 mm | 37.00 mm | 95.75 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 61.98 mm | 71.29 mm | 184.50 mm | n/a | n/a |
Cash remaining | n/a | 1.05 bn | 1.04 bn | 923.50 mm | n/a | n/a |
Runway (months of cash) | n/a | 32.5 | 28.0 | 9.6 | n/a | n/a |
Institutional ownership, Q1 2024
91.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 745 |
Opened positions | 227 |
Closed positions | 111 |
Increased positions | 241 |
Reduced positions | 186 |
13F shares | Current |
---|---|
Total value | 17.78 tn |
Total shares | 144.93 mm |
Total puts | 1.86 mm |
Total calls | 1.04 mm |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 18.25 mm | $2.51 tn |
BLK Blackrock | 13.81 mm | $1.90 tn |
STT State Street | 6.81 mm | $935.46 bn |
Edgewood Management | 6.66 mm | $913.97 bn |
Baillie Gifford & Co | 5.74 mm | $787.72 bn |
Growth Fund Of America | 4.99 mm | $1.50 bn |
Loomis Sayles & Co L P | 4.41 mm | $605.89 mm |
Geode Capital Management | 3.75 mm | $513.58 bn |
JHG Janus Henderson | 3.68 mm | $505.97 bn |
MS Morgan Stanley | 3.61 mm | $495.45 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | Ullem Scott B. | Common Stock | Grant | Acquire A | No | No | 0 | 2,622 | 0.00 | 4,292 |
16 May 24 | Siegel Susan E | Common Stock | Grant | Acquire A | No | No | 0 | 2,622 | 0.00 | 10,630 |
16 May 24 | Schiller Philip W | Common Stock | Grant | Acquire A | No | No | 0 | 2,622 | 0.00 | 16,315 |
16 May 24 | Macmillan Stephen P | Common Stock | Grant | Acquire A | No | No | 0 | 2,622 | 0.00 | 4,129 |
16 May 24 | Gary S Guthart | Common Stock | Grant | Acquire A | No | No | 0 | 2,622 | 0.00 | 12,597 |
News
10 Health Care Stocks With Whale Alerts In Today's Session
14 May 24
Illumina Unusual Options Activity For May 07
7 May 24
Stephens & Co. Reiterates Overweight on Illumina, Maintains $170 Price Target
7 May 24
Scotiabank Maintains Sector Outperform on Illumina, Lowers Price Target to $176
6 May 24
Beyond The Numbers: 6 Analysts Discuss Illumina Stock
3 May 24
Press releases
Integrated Biosciences Joins Illumina Ventures Labs to Design Novel Therapeutics Targeting the Transcriptome
28 May 24
Anna Richo joins Illumina's Board of Directors
20 May 24
Illumina To Webcast Upcoming Investor Conference
15 May 24
GRAIL to Host Capital Markets Day
13 May 24
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
6 May 24